US Edition
Global Burden of Chikungunya Virus Infections and the Potential Benefit of Vaccination Campaigns
3 Articles
3 Articles
Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns
The first vaccine against chikungunya virus (CHIKV) has now been licensed; however, due to a limited knowledge of the underlying global burden, its potential to reduce disease burden remains unknown. We used data from seroprevalence studies, observed cases and mosquito distributions to quantify the underlying CHIKV burden in 180 countries and territories, and we explored the potential impact of vaccination campaigns. We estimate that 104 countri…
Four new non-serious cases of chikungunya vaccine-related adverse reactions have been reported in recent weeks, according to data published on Friday by the drug agency, which has not recorded any new serious cases or deaths. In total, as of June 5, "47 cases of chikungunya vaccine-related adverse reactions have been reported...
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
